Truist Securities Reiterates Buy on Regeneron Pharmaceuticals, Maintains $1050 Price Target
Portfolio Pulse from richadhand@benzinga.com
Truist Securities analyst Robyn Karnauskas reiterated a Buy rating on Regeneron Pharmaceuticals (NASDAQ:REGN) and maintained a $1050 price target.
June 27, 2023 | 1:31 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Truist Securities analyst Robyn Karnauskas reiterated a Buy rating on Regeneron Pharmaceuticals and maintained a $1050 price target.
The reiteration of a Buy rating and maintenance of a $1050 price target by Truist Securities analyst Robyn Karnauskas indicates a positive outlook for Regeneron Pharmaceuticals. This news is likely to have a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100